Rational biomarker development for the early and minimally invasive monitoring of AML

Area of Science:

• Hematology
• Molecular Biology
• Biomarker Discovery

Background:

• Recurrent disease is a primary cause of treatment failure in acute myeloid leukemia (AML).
• Current methods for monitoring AML relapse risk, such as bone marrow surveillance, are invasive and costly.
• Identifying reliable, minimally invasive biomarkers for AML is crucial for timely intervention.

Purpose of the Study:

• To discover novel microRNA (miRNA) biomarkers in extracellular vesicles for early detection of acute myeloid leukemia (AML) relapse.
• To establish a minimally invasive method for monitoring AML disease burden and treatment response.

Main Methods:

• Next-generation sequencing was used to analyze small RNA content within extracellular vesicles from 12 AML patients and 12 healthy controls.
• Differentially expressed miRNAs were identified and validated in preclinical models, including murine models and patient-derived xenografts.

Main Results:

• A unique panel of circulating microRNAs (miRNAs) within extracellular vesicles was identified in AML patients.
• These miRNAs were detected in peripheral blood preceding overt leukemic blast dissemination and bone marrow failure.
• miR-1246 was identified as a potential candidate biomarker for acute myeloid leukemia.

Conclusions:

• Circulating extracellular vesicle-contained miRNAs represent a promising source for minimally invasive biomarkers in acute myeloid leukemia (AML).
• The identified miRNA panel, particularly miR-1246, shows potential for early detection of AML relapse and monitoring disease progression.
• This approach could overcome the limitations of current invasive monitoring techniques, improving patient outcomes.